论文部分内容阅读
目的探讨miR-29a在宫颈癌组织中的表达及与宫颈癌临床病理因素之间的关系。方法用茎-环实时荧光定量PCR分析56例宫颈癌组织和20例正常宫颈组织中miR-29a的表达情况,分析miR-29a的表达与宫颈癌常用临床病理指标的关系。结果茎-环实时荧光定量PCR能特异扩增miR-29a。miR-29a在宫颈癌组织中的表达量明显低于正常宫颈组织(P<0.01)。miR-29a在Ⅱa期宫颈癌组织中的表达量明显低于Ⅰa期和Ⅰb期(P<0.01)。miR-29a的表达和年龄、肿瘤大小、肿瘤类型和病理分级无关(P>0.05)。结论 miR-29a是宫颈癌的重要标记和靶向治疗的潜在靶点。
Objective To investigate the expression of miR-29a in cervical cancer and its relationship with clinicopathological factors. Methods The expression of miR-29a in 56 cases of cervical cancer and 20 cases of normal cervical tissue was analyzed by stem-loop real-time fluorescence quantitative PCR. The relationship between the expression of miR-29a and clinicopathological parameters of cervical cancer was analyzed. Results Stem-loop real-time PCR could specifically amplify miR-29a. The expression of miR-29a in cervical cancer tissues was significantly lower than that in normal cervical tissues (P <0.01). The expression of miR-29a in stage IIa cervical cancer was significantly lower than that in stage Ia and Ib (P <0.01). The expression of miR-29a was not related to age, tumor size, tumor type and pathological grade (P> 0.05). Conclusion miR-29a is an important target of cervical cancer and targeted therapy.